Telomir Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. *Market Information *
Our common stock is listed on The Nasdaq Capital Market under the symbol “TELO” and began trading February 9, 2024.
Holders of Common Stock
As of March 28, 2024, we had approximately 70 holders of record of our common stock. No cash dividends have been paid on the common stock to date. We currently intend to retain earnings for further business development and do not expect to pay cash dividends in the foreseeable future.
Unregistered Sales of Equity Securities and Use of Proceeds
None
Issuer Purchases of Equity Securities
None
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.